Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study

Autor: Meric-Bernstam, Funda *, Beeram, Muralidhar, Hamilton, Erika, Oh, Do-Youn, Hanna, Diana L, Kang, Yoon-Koo, Elimova, Elena, Chaves, Jorge, Goodwin, Rachel, Lee, Jeeyun, Nabell, Lisle, Rha, Sun Young, Mayordomo, Jose, El-Khoueiry, Anthony, Pant, Shubham, Raghav, Kanwal, Kim, Jin Won, Patnaik, Amita, Gray, Todd, Davies, Rupert, Ozog, Mark A, Woolery, Joseph, Lee, Keun-Wook
Zdroj: In The Lancet Oncology December 2022 23(12):1558-1570
Databáze: ScienceDirect